文献速递银屑病与炎症性皮肤病

抗IL-17时代生物制剂药物存留率:时间期校正登记研究

Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
PubMed 文献 · Br J Dermatol · 2021-02-22

校正生物制剂初治状态后,ixekizumab、secukinumab与ustekinumab的12个月存留率相近且优于adalimumab和etanercept;既往生物制剂暴露、新药上市和女性性别增加停药风险。

要点

  • 校正生物制剂初治状态后,ixekizumab、secukinumab与ustekinumab的12个月存留率相近。
  • 既往生物制剂暴露显著增加停药风险(2·10,P < 0·001)。
  • 女性性别增加停药风险(1·50,P = 0·019),银屑病关节炎未见显著影响。

核心结论

  • 校正生物制剂初治状态后,ixekizumab、secukinumab与ustekinumab的12个月存留率相近,且均优于adalimumab和etanercept。
  • 分析药物存留率时应考虑药物可获得性的时间依赖性变化。
  • 既往生物制剂暴露显著影响药物存留,女性更易停药。

研究设计与样本

  • 共纳入1572例患者、1848个治疗周期。

主要发现

  • 长期PASI改善最高见于ixekizumab,其次为ustekinumab、secukinumab、adalimumab和etanercept。
  • 总体未校正分析中,ustekinumab在48个月内的药物存留率优于其他所有生物制剂。
  • 校正生物制剂初治状态后,12个月及以后存留率:ixekizumab 91·6%、secukinumab 90·2%、ustekinumab 92·8%,均优于adalimumab 76·5%和etanercept 71·9%。
  • 既往生物制剂非初治(2·10,P < 0·001)、新药如secukinumab或ixekizumab上市(相对风险比1·6,P = 0·001)及女性性别(1·50,P = 0·019)增加总体停药风险。
  • 银屑病关节炎未显著增加停药风险(1·12,P = 0·21)。

关键数值与推荐

  • 12个月及以后药物存留率:ixekizumab 91·6%、secukinumab 90·2%、ustekinumab 92·8%、adalimumab 76·5%、etanercept 71·9%(校正生物制剂初治状态后)。
  • 停药风险:既往生物制剂非初治2·10(P < 0·001);新药上市相对风险比1·6(P = 0·001);女性1·50(P = 0·019);银屑病关节炎1·12(P = 0·21)。

临床怎么用

  • 在比较生物制剂药物存留率时,应考虑药物上市时间及治疗选项可获得性的影响。
  • 处方前应了解患者既往生物制剂暴露史,其与更高的停药风险相关。
  • 女性患者可能需要更多关注以维持治疗持续性。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time-dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. OBJECTIVES: To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment. METHODS: This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019. RESULTS: A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long-term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non-naïvety (2·10, P < 0·001), the introduction of a new drug such as secukinumab or ixekizumab (relative hazard ratio 1·6, P = 0·001) and female gender (1·50, P = 0·019) increased the risk of treatment discontinuation overall, whereas psoriatic arthritis did not (1·12, P = 0·21). CONCLUSIONS: The time-dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021. PMID: 33289075. doi:10.1111/bjd.19701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。